Section 14982 Of Chapter 12. Purchase Of Prescription Drugs For Government Agencies From California Government Code >> Division 3. >> Title 2. >> Part 5.5. >> Chapter 12.
14982
. (a) It is the intent of the Legislature that the Department
of General Services, University of California, and the Public
Employees' Retirement System regularly meet and share information
regarding each agency's procurement of prescription drugs in an
effort to identify and implement opportunities for cost savings in
connection with this procurement. It is the intent of the Legislature
that the University of California and the Public Employees'
Retirement System cooperate with the department in order to reduce
each agency's costs for prescription drugs.
(b) The department shall do all of the following:
(1) Share information on a regular basis with the University of
California and the Public Employees' Retirement System regarding each
agency's procurement of prescription drugs, including, but not
limited to, prices paid for the same or similar drugs and information
regarding drug effectiveness.
(2) Identify opportunities for the department, the University of
California, and the Public Employees' Retirement System to
consolidate drug procurement or engage in other joint activities that
will result in cost savings in the procurement of prescription
drugs.
(3) Participate in at least one independent association that
develops information on the relative effectiveness of prescription
drugs.
(4) Develop strategies, in consultation with the affected
agencies, for the state to achieve savings through greater use of
generic drugs.
(5) No later than January 1, 2006, and annually thereafter,
develop a workplan that includes, but is not limited to, a
description of the department's annual activities to reduce the state'
s costs for prescription drugs and an estimate of cost savings.
(c) Nothing in this section shall be construed to require sharing
of information that is prohibited by any other provision of law or
contractual agreement, or the disclosure of information that may
adversely affect potential drug procurement by any state agency.